BioInvent International AB (OMXS: BINV) today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.™.
Traditional drug discovery methods involve the identification of drugs candidates that bind to known disease targets. The F.I.R.S.T.™ technology is a novel and unique discovery method, which allows for antibodies and disease targets to be identified simultaneously.
BioInvent has used F.I.R.S.T.™ successfully in several proprietary discovery projects and offers F.I.R.S.T.™ as well as traditional antibody discovery screening to commercial partners.
"With billions of binders available in the libraries and state-of-the-art in vitro and in vivo cancer and immunological assays, we can discover antibodies with the very best properties for onward development." Said Björn Frendeus, VP Preclinical Research at BioInvent.
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery